{"hands_on_practices": [{"introduction": "The diagnostic journey for thrombocytopenia begins with a single, crucial number: the platelet count. Before launching into a complex investigation, it is imperative to ensure this number is accurate. This exercise [@problem_id:4828587] addresses a common clinical pitfall—pseudothrombocytopenia—by asking you to derive and apply a correction factor for a diluted sample, a fundamental skill that prevents misdiagnosis and ensures the entire subsequent workup is built on a solid foundation.", "problem": "A $62$-year-old patient with suspected Ethylenediaminetetraacetic acid (EDTA)-dependent pseudothrombocytopenia undergoes repeat platelet counting using a sodium citrate tube to avoid in vitro clumping. The sodium citrate tube contains a fixed anticoagulant volume $V_{c} = 0.5\\,\\mathrm{mL}$ (standard $3.2\\%$ sodium citrate, $0.109\\,\\mathrm{M}$), and on this draw the tube is underfilled with blood to $V_{b} = 4.0\\,\\mathrm{mL}$. The hematology analyzer reports the platelet concentration of the diluted blood–citrate mixture based on the sampled mixture volume. The measured platelet count from this citrate tube is $68 \\times 10^{9}/\\mathrm{L}$.\n\nStarting from the core definitions that concentration is the number of particles per unit volume and that the number of platelets in the sample is conserved by dilution (that is, the anticoagulant adds volume without changing the number of platelets), derive the dilution correction factor from first principles and apply it to compute the whole-blood equivalent platelet count that should be used in the diagnostic approach to thrombocytopenia. Round your final numeric answer to three significant figures and express it in the unit $10^{9}/\\mathrm{L}$.", "solution": "The problem is valid as it is scientifically grounded in the principles of solution dilution, clinically relevant to the diagnosis of thrombocytopenia, and provides a self-contained, well-posed set of conditions for a unique solution.\n\nThe goal is to determine the true platelet concentration in a patient's whole blood, $C_{\\text{true}}$, given the measured concentration in a sample diluted with anticoagulant, $C_{\\text{measured}}$. We begin from the fundamental definition of concentration ($C$) as the number of particles ($N$) per unit volume ($V$):\n$$C = \\frac{N}{V}$$\nFrom this, the total number of platelets, $N_{\\text{plt}}$, in the initial whole blood sample of volume $V_{b}$ is:\n$$N_{\\text{plt}} = C_{\\text{true}} \\cdot V_{b}$$\nThe problem states that the blood sample is drawn into a tube containing a volume $V_{c}$ of sodium citrate anticoagulant. The problem provides the following values:\n- Volume of blood, $V_{b} = 4.0\\,\\mathrm{mL}$\n- Volume of citrate anticoagulant, $V_{c} = 0.5\\,\\mathrm{mL}$\n\nA core principle provided is that the number of platelets is conserved upon dilution. The anticoagulant adds volume but does not change the total number of platelets in the tube. The total volume of the mixture in the tube, $V_{\\text{total}}$, is the sum of the blood and anticoagulant volumes:\n$$V_{\\text{total}} = V_{b} + V_{c}$$\nThe hematology analyzer measures the platelet concentration of this diluted mixture, reported as $C_{\\text{measured}} = 68 \\times 10^{9}/\\mathrm{L}$. The total number of platelets in this diluted volume is:\n$$N_{\\text{plt}} = C_{\\text{measured}} \\cdot V_{\\text{total}}$$\nBy the principle of conservation of platelets, we can equate the two expressions for $N_{\\text{plt}}$:\n$$C_{\\text{true}} \\cdot V_{b} = C_{\\text{measured}} \\cdot V_{\\text{total}}$$\nSubstituting the expression for $V_{\\text{total}}$ gives:\n$$C_{\\text{true}} \\cdot V_{b} = C_{\\text{measured}} \\cdot (V_{b} + V_{c})$$\nTo find the true, undiluted blood platelet concentration, we solve for $C_{\\text{true}}$:\n$$C_{\\text{true}} = C_{\\text{measured}} \\cdot \\frac{V_{b} + V_{c}}{V_{b}}$$\nThe term $\\frac{V_{b} + V_{c}}{V_{b}}$ is the dilution correction factor, $F_{\\text{dilution}}$, which must be applied to the measured concentration. The problem requires deriving this factor from first principles, which we have done. We can also express it as:\n$$F_{\\text{dilution}} = 1 + \\frac{V_{c}}{V_{b}}$$\nNow, we substitute the given numerical values into this expression to calculate the correction factor:\n$$F_{\\text{dilution}} = \\frac{4.0\\,\\mathrm{mL} + 0.5\\,\\mathrm{mL}}{4.0\\,\\mathrm{mL}} = \\frac{4.5}{4.0} = 1.125$$\nThis factor is dimensionless. Finally, we calculate the whole-blood equivalent platelet count, $C_{\\text{true}}$, by multiplying the measured count by this factor:\n$$C_{\\text{true}} = C_{\\text{measured}} \\cdot F_{\\text{dilution}}$$\n$$C_{\\text{true}} = (68 \\times 10^{9}/\\mathrm{L}) \\cdot 1.125$$\n$$C_{\\text{true}} = 76.5 \\times 10^{9}/\\mathrm{L}$$\nThe problem asks for the final answer to be rounded to three significant figures. The calculated value $76.5$ already contains three significant figures. Expressed in the required units, the numerical value is $76.5$. This corrected value should be used in the diagnostic assessment of the patient's thrombocytopenia.", "answer": "$$\\boxed{76.5}$$", "id": "4828587"}, {"introduction": "With a confirmed low platelet count, the next critical step is to determine the underlying pathophysiology: is the bone marrow failing to produce platelets, or are they being rapidly destroyed in the periphery? The Immature Platelet Fraction (IPF) provides a direct window into bone marrow activity. This practice problem [@problem_id:4828623] challenges you to use a high IPF value, in conjunction with the overall clinical context, to deduce the mechanism of thrombocytopenia and select the most appropriate diagnostic pathway, showcasing how a single data point can guide complex clinical reasoning.", "problem": "A $52$-year-old man presents with new-onset easy bruising and mild gum bleeding over $3$ weeks. He denies fever, confusion, focal neurologic symptoms, recent infections, and has had no recent hospitalizations or exposure to heparin. He takes lisinopril and atorvastatin, both for more than $2$ years without recent dose changes, and drinks approximately $1$ alcoholic beverage per day. He has no known chronic liver disease. Examination reveals scattered ecchymoses, no petechiae, no hepatosplenomegaly, and normal vital signs. Laboratory results: hemoglobin $13.8\\,\\text{g/dL}$, white blood cell (WBC) count $6.2\\times 10^9/\\text{L}$, platelet count $40\\times 10^9/\\text{L}$, prothrombin time $12.2\\,\\text{s}$, activated partial thromboplastin time $33.8\\,\\text{s}$, fibrinogen $3.1\\,\\text{g/L}$, and D-dimer $0.32\\,\\mu\\text{g/mL}$ (reference 0.5). The laboratory also reports an Immature Platelet Fraction (IPF) of $18\\%$.\n\nStarting from core definitions of platelet kinetics and hematopoiesis: let platelet production rate be $P$ (platelets per unit time), platelet lifespan be $L$ (time), and the steady-state platelet count be $C$. In a simplified steady-state framework, $C$ scales with the product $P\\times L$. The IPF estimates the proportion of circulating platelets that are newly released, and is expected to increase when marrow production rises relative to the circulating count. Use these fundamentals to infer the most likely pathophysiology driving this patient’s thrombocytopenia and identify the most appropriate immediate next diagnostic steps.\n\nWhich option best fits the data and the reasoning from first principles?\n\nA. Predominant peripheral platelet destruction or consumption with compensatory marrow response; first exclude pseudothrombocytopenia and evaluate for immune or secondary causes with a peripheral blood smear (including assessment for clumping and schistocytes), human immunodeficiency virus (HIV) and hepatitis C virus (HCV) serologies, and a careful medication and systemic disease review.\n\nB. Primary bone marrow failure with impaired platelet production; proceed directly to urgent bone marrow biopsy and initiate a thrombopoietin receptor agonist empirically.\n\nC. Splenic sequestration due to portal hypertension; obtain immediate abdominal ultrasonography and give prophylactic platelet transfusions to raise the count above $50\\times 10^9/\\text{L}$ for diagnostic procedures.\n\nD. Thrombotic thrombocytopenic purpura (TTP) with microangiopathic hemolytic anemia; initiate emergent plasma exchange based on the elevated IPF without additional testing.\n\nE. Heparin-induced thrombocytopenia (HIT); order platelet factor $4$ (PF$4$) antibody testing despite no heparin exposure and otherwise reassuring clinical context.", "solution": "The problem statement is evaluated as scientifically sound, well-posed, and internally consistent. All provided clinical and laboratory data are plausible and sufficient for a rigorous diagnostic inference. The problem does not violate any validation criteria.\n\nThe core of the problem lies in the interpretation of platelet kinetics using the provided framework and laboratory data. The steady-state platelet count, $C$, is stated to be proportional to the product of the production rate, $P$, and the platelet lifespan, $L$:\n$$C \\propto P \\times L$$\nThe patient presents with thrombocytopenia, which is a decreased platelet count. The provided count is $C = 40 \\times 10^9/\\text{L}$, which is significantly below the normal range (typically $150-450 \\times 10^9/\\text{L}$). Based on the equation, a low $C$ must be due to a decrease in $P$, a decrease in $L$, or both. Splenic sequestration can also lower the circulating count, $C$, by sequestering a larger fraction of the total platelet mass.\n\nThe crucial piece of data is the Immature Platelet Fraction (IPF), which is $18\\%$. A normal IPF is typically below $7\\%$. The problem correctly states that IPF increases when marrow production rises relative to the circulating count. A markedly elevated IPF of $18\\%$ is a strong indicator of a hyperproliferative bone marrow response, meaning the platelet production rate, $P$, is significantly increased.\n\nApplying this to the kinetic model, if $P$ is high and $C$ is low, the equation $C \\propto P \\times L$ can only be balanced if the platelet lifespan, $L$, is substantially decreased. This points unequivocally to a pathophysiology dominated by peripheral platelet destruction or consumption, not by impaired production.\n\nFurther analysis of the provided data supports this conclusion and helps narrow the differential diagnosis:\n1.  **Isolated Thrombocytopenia:** The hemoglobin ($13.8\\,\\text{g/dL}$) and white blood cell count ($6.2\\times 10^9/\\text{L}$) are normal. This makes a primary bone marrow failure (e.g., aplastic anemia, myelodysplasia, acute leukemia), which would typically affect multiple cell lines, a much less likely diagnosis.\n2.  **No Evidence of DIC:** Prothrombin time ($12.2\\,\\text{s}$), activated partial thromboplastin time ($33.8\\,\\text{s}$), fibrinogen ($3.1\\,\\text{g/L}$), and D-dimer ($0.32\\,\\mu\\text{g/mL}$) are all within normal limits. This effectively rules out Disseminated Intravascular Coagulation (DIC) as the cause of consumptive thrombocytopenia.\n3.  **No Evidence of Splenomegaly:** The physical exam reveals no hepatosplenomegaly, making significant splenic sequestration an improbable primary cause.\n4.  **Clinical Context:** The patient's history lacks features suggestive of certain urgent conditions. There is no heparin exposure, ruling out heparin-induced thrombocytopenia (HIT). The absence of fever, neurologic symptoms, and significant anemia argues against the classic presentation of thrombotic thrombocytopenic purpura (TTP).\n\nTherefore, the most likely diagnosis is a condition characterized by peripheral, likely immune-mediated, platelet destruction. Immune Thrombocytopenia (ITP), either primary or secondary to other conditions (e.g., infections, autoimmune diseases, drugs), fits this profile perfectly. The appropriate immediate diagnostic plan is to confirm the diagnosis and investigate potential underlying causes.\n\nNow, we evaluate each option:\n\n**A. Predominant peripheral platelet destruction or consumption with compensatory marrow response; first exclude pseudothrombocytopenia and evaluate for immune or secondary causes with a peripheral blood smear (including assessment for clumping and schistocytes), human immunodeficiency virus (HIV) and hepatitis C virus (HCV) serologies, and a careful medication and systemic disease review.**\nThis option correctly identifies the pathophysiology of peripheral destruction with a compensatory marrow response, which is directly derived from the low platelet count and high IPF. The proposed diagnostic steps are precisely the standard of care for new-onset isolated thrombocytopenia:\n- A peripheral blood smear is critical to rule out pseudothrombocytopenia (an artifact from EDTA-induced platelet clumping) and to search for schistocytes (which would raise concern for a microangiopathic process like TTP, despite the atypical presentation) or other morphologic abnormalities.\n- Testing for HIV and HCV is essential as these are well-known causes of secondary ITP.\n- A thorough review of medications and systemic symptoms is necessary to identify other potential secondary etiologies.\nThis entire approach is logical, evidence-based, and directly follows from the initial data.\n**Verdict: Correct.**\n\n**B. Primary bone marrow failure with impaired platelet production; proceed directly to urgent bone marrow biopsy and initiate a thrombopoietin receptor agonist empirically.**\nThis option proposes a pathophysiology of impaired production. This is directly contradicted by the high IPF of $18\\%$, which indicates robust marrow production. The normal hemoglobin and WBC count also argue against a global marrow failure. Proceeding directly to a bone marrow biopsy is overly invasive at this stage, and initiating a thrombopoietin receptor agonist empirically without a diagnosis is inappropriate.\n**Verdict: Incorrect.**\n\n**C. Splenic sequestration due to portal hypertension; obtain immediate abdominal ultrasonography and give prophylactic platelet transfusions to raise the count above $50\\times 10^9/\\text{L}$ for diagnostic procedures.**\nThis option is unlikely. The physical exam is negative for splenomegaly, a key feature of significant sequestration. While the patient consumes alcohol, the amount is modest and there is no known history of chronic liver disease; the normal coagulation studies also argue against significant hepatic dysfunction. Prophylactic platelet transfusion is generally contraindicated in destructive thrombocytopenias like ITP as the transfused platelets are rapidly destroyed and it may increase thrombotic risk. Transfusion is reserved for severe, active bleeding.\n**Verdict: Incorrect.**\n\n**D. Thrombotic thrombocytopenic purpura (TTP) with microangiopathic hemolytic anemia; initiate emergent plasma exchange based on the elevated IPF without additional testing.**\nWhile TTP is a critical diagnosis to consider in any severe thrombocytopenia, the clinical picture is not classic. There is no fever, neurologic deficit, or significant anemia (hemolysis in TTP would cause anemia). Most importantly, initiating emergent plasma exchange, a major and resource-intensive therapy with significant risks, without first confirming the presence of microangiopathy via a peripheral blood smear (i.e., finding schistocytes) is a deviation from standard practice and potentially dangerous. The high IPF is consistent with TTP's consumptive picture but is not diagnostic.\n**Verdict: Incorrect.**\n\n**E. Heparin-induced thrombocytopenia (HIT); order platelet factor $4$ (PF$4$) antibody testing despite no heparin exposure and otherwise reassuring clinical context.**\nThis option is patently illogical. The problem statement explicitly gives \"no exposure to heparin\" as a key negative historical point. HIT is an immune reaction to heparin-PF4 complexes. Without exposure to heparin, the diagnosis is impossible. Ordering a test with a pre-test probability of zero is clinically and scientifically unjustifiable.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4828623"}, {"introduction": "In the evaluation of thrombocytopenia, certain diagnoses are medical emergencies that require rapid and accurate risk stratification. Heparin-Induced Thrombocytopenia (HIT) is a prime example. This exercise [@problem_id:4828571] provides hands-on practice with the 4T score, a validated clinical prediction rule, and then takes it a step further by using Bayesian principles to update a pre-test probability. Mastering this process is essential for translating clinical suspicion into a quantitative risk assessment, directly guiding critical management decisions.", "problem": "A $58$-year-old woman with acute pulmonary embolism was started on therapeutic unfractionated heparin on hospital day $0$. Her baseline platelet count was $240 \\times 10^{9}/\\mathrm{L}$. On hospital day $5$, her platelet count is $90 \\times 10^{9}/\\mathrm{L}$, with the nadir documented at $90 \\times 10^{9}/\\mathrm{L}$. She has new right lower extremity deep vein thrombosis confirmed by compression ultrasonography on hospital day $6$. There is no clinical or laboratory evidence of disseminated intravascular coagulation, no recent chemotherapeutic agents, and no other medications newly initiated except heparin; there are no features suggestive of sepsis, and blood cultures are negative. She has not received heparin in the preceding $100$ days.\n\nUsing the commonly employed four-component clinical prediction rule for heparin-induced thrombocytopenia (HIT), compute her score by integrating the following four domains: degree of thrombocytopenia, timing of platelet count fall, thrombosis or other sequelae, and the presence of other plausible causes of thrombocytopenia. Classify the score into low, intermediate, or high probability strata.\n\nYour institution has validated the following stratum-specific diagnostic likelihood ratios for HIT when the prediction rule is applied:\n- Low stratum likelihood ratio: $LR_{\\mathrm{low}} = 0.10$.\n- Intermediate stratum likelihood ratio: $LR_{\\mathrm{int}} = 1.8$.\n- High stratum likelihood ratio: $LR_{\\mathrm{high}} = 6.0$.\n\nAssume the clinician’s pretest probability for HIT prior to applying the prediction rule in this patient is $p_{0} = 0.08$. Using an evidence-based framework for updating probability based on stratum-specific likelihood ratios, determine:\n1. The post-test probability of HIT if the score falls into the low, intermediate, and high strata (provide the analytic expressions and their numerical values).\n2. The patient’s post-test probability of HIT given her computed score and stratum.\n\nExpress the final answer as the patient’s post-test probability of HIT in decimal form without a percent sign, and round to four significant figures.", "solution": "The problem will be addressed by first validating its premises and then proceeding to a structured solution.\n\n### Step 1: Extract Givens\n- Patient age: $58$ years\n- Diagnosis: Acute pulmonary embolism\n- Treatment initiated on hospital day $0$: therapeutic unfractionated heparin\n- Baseline platelet count (day $0$): $P_0 = 240 \\times 10^{9}/\\mathrm{L}$\n- Platelet count on hospital day $5$: $P_5 = 90 \\times 10^{9}/\\mathrm{L}$\n- Platelet nadir: $P_{\\text{nadir}} = 90 \\times 10^{9}/\\mathrm{L}$\n- New event on hospital day $6$: confirmed right lower extremity deep vein thrombosis\n- Exclusions: no disseminated intravascular coagulation, no recent chemotherapy, no other new medications, no sepsis, negative blood cultures\n- Heparin history: no exposure in the preceding $100$ days\n- Prediction rule: Four-component clinical prediction rule for heparin-induced thrombocytopenia (HIT)\n- Likelihood Ratios (LRs) for the prediction rule:\n  - Low stratum: $LR_{\\mathrm{low}} = 0.10$\n  - Intermediate stratum: $LR_{\\mathrm{int}} = 1.8$\n  - High stratum: $LR_{\\mathrm{high}} = 6.0$\n- Pretest probability of HIT: $p_{0} = 0.08$\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective. It presents a realistic clinical scenario and asks for the application of a standard, validated clinical prediction rule (the 4T score for HIT) and a standard statistical method (Bayesian updating using likelihood ratios). The data provided are internally consistent and complete for the task. The problem does not violate any fundamental principles, is not based on false premises, and uses precise, unambiguous language. The numerical values for platelet counts and likelihood ratios are within realistic ranges for this clinical context.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid. A solution will be provided.\n\n### Solution\nThe solution involves two main steps: first, calculating the patient's score on the four-component clinical prediction rule (the 4T score) to determine her risk stratum; second, using the provided pretest probability and stratum-specific likelihood ratio to calculate the post-test probability of HIT.\n\n#### Part 1: Calculation of the 4T Score\nThe 4T score is calculated by assigning points for four domains: Thrombocytopenia, Timing, Thrombosis, and oTher causes.\n\n1.  **Thrombocytopenia:** The degree of platelet count fall is assessed.\n    The baseline platelet count is $P_0 = 240 \\times 10^{9}/\\mathrm{L}$.\n    The nadir platelet count is $P_{\\text{nadir}} = 90 \\times 10^{9}/\\mathrm{L}$.\n    The absolute platelet count fall is $P_0 - P_{\\text{nadir}} = 240 - 90 = 150 \\times 10^{9}/\\mathrm{L}$.\n    The percentage platelet count fall is calculated as:\n    $$ \\text{Fall Percentage} = \\frac{P_0 - P_{\\text{nadir}}}{P_0} \\times 100\\% = \\frac{150 \\times 10^{9}}{240 \\times 10^{9}} \\times 100\\% = 0.625 \\times 100\\% = 62.5\\% $$\n    The scoring criteria for this component are:\n    - 2 points: Platelet count fall $ 50\\%$ or nadir $\\ge 20 \\times 10^{9}/\\mathrm{L}$.\n    - 1 point: Platelet count fall $30\\%-50\\%$ or nadir $10-19 \\times 10^{9}/\\mathrm{L}$.\n    - 0 points: Platelet count fall $ 30\\%$ or nadir $ 10 \\times 10^{9}/\\mathrm{L}$.\n    The patient's fall of $62.5\\%$ is greater than $50\\%$, and her nadir of $90 \\times 10^{9}/\\mathrm{L}$ is greater than $20 \\times 10^{9}/\\mathrm{L}$. This component scores **2 points**.\n\n2.  **Timing of Platelet Count Fall:** The onset of thrombocytopenia relative to heparin exposure is assessed.\n    Heparin was initiated on day $0$. The platelet count drop was noted on day $5$. The patient has not had heparin exposure in the prior $100$ days.\n    The scoring criteria are:\n    - 2 points: Clear onset between days $5-10$ of heparin exposure, or $\\le 1$ day if there was heparin exposure within the last $30$ days.\n    - 1 point: Onset consistent with days $5-10$ but not clear, or onset after day $10$, or onset $\\le 1$ day with heparin exposure $30-100$ days ago.\n    - 0 points: Platelet count fall at $\\le 4$ days without recent exposure.\n    The onset on day $5$ is characteristic of typical-onset HIT in a heparin-naive patient. This component scores **2 points**.\n\n3.  **Thrombosis or Other Sequelae:** The presence of new thrombosis or other HIT-related events is assessed.\n    The patient developed a new, confirmed right lower extremity deep vein thrombosis on day $6$.\n    The scoring criteria are:\n    - 2 points: New, confirmed thrombosis; skin necrosis at injection sites; acute systemic reaction after IV heparin bolus.\n    - 1 point: Recurrent or progressive thrombosis; non-necrotic skin lesions; suspected but unproven thrombosis.\n    - 0 points: No sequelae.\n    The patient has a new, confirmed thrombosis. This component scores **2 points**.\n\n4.  **oTher Causes for Thrombocytopenia:** The possibility of alternative explanations for the platelet drop is considered.\n    The problem statement explicitly rules out common alternative causes: \"no clinical or laboratory evidence of disseminated intravascular coagulation, no recent chemotherapeutic agents, and no other medications newly initiated except heparin; there are no features suggestive of sepsis, and blood cultures are negative.\"\n    The scoring criteria are:\n    - 2 points: No other cause for thrombocytopenia is apparent.\n    - 1 point: A possible other cause is present.\n    - 0 points: A definite other cause is present.\n    Based on the information provided, no other cause is apparent. This component scores **2 points**.\n\n**Total 4T Score:**\nThe total score is the sum of the points from each component: $2 + 2 + 2 + 2 = 8$.\n\n**Risk Stratification:**\nThe total score is used to classify the pretest probability of HIT into one of three strata:\n- Low probability: $0-3$ points\n- Intermediate probability: $4-5$ points\n- High probability: $6-8$ points\nWith a score of $8$, the patient falls into the **high probability** stratum.\n\n#### Part 2: Calculation of Post-test Probability\nThe post-test probability of HIT is calculated by updating the pretest probability using the likelihood ratio corresponding to the patient's risk stratum. This is done using Bayes' theorem, commonly applied in the form of odds.\n\nThe relationship between probability ($p$) and odds ($O$) is given by:\n$$ O = \\frac{p}{1-p} \\quad \\text{and} \\quad p = \\frac{O}{1+O} $$\n\nThe updating formula is:\n$$ \\text{Post-test Odds} = \\text{Pre-test Odds} \\times \\text{Likelihood Ratio} $$\n\nThe given pretest probability is $p_0 = 0.08$. The pretest odds ($O_0$) are:\n$$ O_0 = \\frac{p_0}{1-p_0} = \\frac{0.08}{1 - 0.08} = \\frac{0.08}{0.92} = \\frac{8}{92} = \\frac{2}{23} $$\n\n**1. Post-test Probabilities for Each Stratum**\n\n**a) Low Stratum:**\nUsing $LR_{\\mathrm{low}} = 0.10$:\n$$ O_{\\text{post, low}} = O_0 \\times LR_{\\mathrm{low}} = \\frac{2}{23} \\times 0.10 = \\frac{2}{230} = \\frac{1}{115} $$\nThe post-test probability for the low stratum, $p_{\\text{post, low}}$, is:\n$$ p_{\\text{post, low}} = \\frac{O_{\\text{post, low}}}{1 + O_{\\text{post, low}}} = \\frac{1/115}{1 + 1/115} = \\frac{1/115}{116/115} = \\frac{1}{116} \\approx 0.008621 $$\nThe analytical expression is $p_{\\text{post, low}} = \\frac{\\frac{p_0}{1-p_0} LR_{\\mathrm{low}}}{1 + \\frac{p_0}{1-p_0} LR_{\\mathrm{low}}}$.\n\n**b) Intermediate Stratum:**\nUsing $LR_{\\mathrm{int}} = 1.8$:\n$$ O_{\\text{post, int}} = O_0 \\times LR_{\\mathrm{int}} = \\frac{2}{23} \\times 1.8 = \\frac{3.6}{23} = \\frac{36}{230} = \\frac{18}{115} $$\nThe post-test probability for the intermediate stratum, $p_{\\text{post, int}}$, is:\n$$ p_{\\text{post, int}} = \\frac{O_{\\text{post, int}}}{1 + O_{\\text{post, int}}} = \\frac{18/115}{1 + 18/115} = \\frac{18/115}{133/115} = \\frac{18}{133} \\approx 0.1353 $$\nThe analytical expression is $p_{\\text{post, int}} = \\frac{\\frac{p_0}{1-p_0} LR_{\\mathrm{int}}}{1 + \\frac{p_0}{1-p_0} LR_{\\mathrm{int}}}$.\n\n**c) High Stratum:**\nUsing $LR_{\\mathrm{high}} = 6.0$:\n$$ O_{\\text{post, high}} = O_0 \\times LR_{\\mathrm{high}} = \\frac{2}{23} \\times 6.0 = \\frac{12}{23} $$\nThe post-test probability for the high stratum, $p_{\\text{post, high}}$, is:\n$$ p_{\\text{post, high}} = \\frac{O_{\\text{post, high}}}{1 + O_{\\text{post, high}}} = \\frac{12/23}{1 + 12/23} = \\frac{12/23}{35/23} = \\frac{12}{35} $$\nThe analytical expression is $p_{\\text{post, high}} = \\frac{\\frac{p_0}{1-p_0} LR_{\\mathrm{high}}}{1 + \\frac{p_0}{1-p_0} LR_{\\mathrm{high}}}$.\n\n**2. The Patient's Specific Post-test Probability**\nThe patient's 4T score of $8$ places her in the **high probability** stratum. Therefore, her specific post-test probability of HIT is $p_{\\text{post, high}}$.\n$$ p_{\\text{patient}} = \\frac{12}{35} \\approx 0.34285714... $$\nRounding this value to four significant figures gives $0.3429$.", "answer": "$$\\boxed{0.3429}$$", "id": "4828571"}]}